Jennifer L Brogdon
Overview
Explore the profile of Jennifer L Brogdon including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
31
Citations
5028
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Bhagwat A, Torres L, Shestova O, Shestov M, Mellors P, Fisher H, et al.
Nat Med
. 2024 Sep;
30(12):3697-3708.
PMID: 39333315
Acute myeloid leukemia (AML) is a rapidly progressive malignancy without effective therapies for refractory disease. So far, chimeric antigen receptor (CAR) T cell therapy in AML has not recapitulated the...
2.
Bagley S, Binder Z, Lamrani L, Marinari E, Desai A, Nasrallah M, et al.
Nat Cancer
. 2024 Jan;
5(3):517-531.
PMID: 38216766
We previously showed that chimeric antigen receptor (CAR) T-cell therapy targeting epidermal growth factor receptor variant III (EGFRvIII) produces upregulation of programmed death-ligand 1 (PD-L1) in the tumor microenvironment (TME)....
3.
Haas A, Golden R, Litzky L, Engels B, Zhao L, Xu F, et al.
Mol Ther
. 2023 Jun;
31(8):2309-2325.
PMID: 37312454
Multiple clinical studies have treated mesothelin (MSLN)-positive solid tumors by administering MSLN-directed chimeric antigen receptor (CAR) T cells. Although these products are generally safe, efficacy is limited. Therefore, we generated...
4.
Dickinson M, Barba P, Jager U, Shah N, Blaise D, Briones J, et al.
Cancer Discov
. 2023 May;
13(9):1982-1997.
PMID: 37249512
Significance: Traditional CAR T-cell manufacturing requires extended ex vivo cell culture, reducing naive and stem cell memory T-cell populations and diminishing antitumor activity. YTB323, which expresses the same validated CAR...
5.
Melenhorst J, Chen G, Wang M, Porter D, Chen C, Collins M, et al.
Nature
. 2022 Dec;
612(7941):E22.
PMID: 36477542
No abstract available.
6.
Garfall A, Cohen A, Susanibar-Adaniya S, Hwang W, Vogl D, Waxman A, et al.
Blood Cancer Discov
. 2022 Nov;
4(2):118-133.
PMID: 36413381
Significance: CAR T cells in early lines of MM therapy could be safer and more effective than in the advanced setting, where prior studies have focused. We evaluated the safety,...
7.
Gill S, Vides V, Frey N, Hexner E, Metzger S, OBrien M, et al.
Blood Adv
. 2022 Mar;
6(21):5774-5785.
PMID: 35349631
In chronic lymphocytic leukemia (CLL) patients who achieve a complete remission (CR) to anti-CD19 chimeric antigen receptor T cells (CART-19), remissions are remarkably durable. Preclinical data suggesting synergy between CART-19...
8.
Melenhorst J, Chen G, Wang M, Porter D, Chen C, Collins M, et al.
Nature
. 2022 Feb;
602(7897):503-509.
PMID: 35110735
The adoptive transfer of T lymphocytes reprogrammed to target tumour cells has demonstrated potential for treatment of various cancers. However, little is known about the long-term potential and clonal stability...
9.
Myers R, Li Y, Leahy A, Barrett D, Teachey D, Callahan C, et al.
J Clin Oncol
. 2021 Jun;
39(27):3044-3055.
PMID: 34156874
Purpose: CD19-targeted chimeric antigen receptor (CAR)-modified T cells demonstrate unprecedented responses in B-cell acute lymphoblastic leukemia (B-ALL); however, relapse remains a substantial challenge. Short CAR T-cell persistence contributes to this...
10.
Singh N, Frey N, Engels B, Barrett D, Shestova O, Ravikumar P, et al.
Nat Med
. 2021 Apr;
27(5):842-850.
PMID: 33888899
While CD19-directed chimeric antigen receptor (CAR) T cells can induce remission in patients with B cell acute lymphoblastic leukemia (ALL), a large subset relapse with CD19 disease. Like CD19, CD22...